168 related articles for article (PubMed ID: 26503205)
1. Targeting Programmed Cell Death 1 in Ovarian Cancer.
Homicsko K; Coukos G
J Clin Oncol; 2015 Dec; 33(34):3987-9. PubMed ID: 26503205
[No Abstract] [Full Text] [Related]
2. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
Hamanishi J; Mandai M; Ikeda T; Minami M; Kawaguchi A; Murayama T; Kanai M; Mori Y; Matsumoto S; Chikuma S; Matsumura N; Abiko K; Baba T; Yamaguchi K; Ueda A; Hosoe Y; Morita S; Yokode M; Shimizu A; Honjo T; Konishi I
J Clin Oncol; 2015 Dec; 33(34):4015-22. PubMed ID: 26351349
[TBL] [Abstract][Full Text] [Related]
3. Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives.
Pujade-Lauraine E; Banerjee S; Pignata S
J Clin Oncol; 2019 Sep; 37(27):2437-2448. PubMed ID: 31403868
[No Abstract] [Full Text] [Related]
4. Successful treatment of refractory leiomyosarcoma with the PD-1 inhibitor nivolumab.
Heine A; Kristiansen G; Schild HH; Brossart P
Ann Oncol; 2016 Sep; 27(9):1813-4. PubMed ID: 27329248
[No Abstract] [Full Text] [Related]
5. Salvage treatment of ovarian cancer.
Muggia FM
J Clin Oncol; 1997 Nov; 15(11):3420-1. PubMed ID: 9363877
[No Abstract] [Full Text] [Related]
6. Activity of immune checkpoint inhibition in platinum refractory germ-cell tumors.
Zschäbitz S; Lasitschka F; Jäger D; Grüllich C
Ann Oncol; 2016 Jul; 27(7):1356-60. PubMed ID: 27029705
[No Abstract] [Full Text] [Related]
7. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy.
Bookman MA
Oncologist; 1999; 4(2):87-94. PubMed ID: 10337378
[TBL] [Abstract][Full Text] [Related]
8. Salvage therapy for recurrent epithelial ovarian cancer.
Baker VV
Hematol Oncol Clin North Am; 2003 Aug; 17(4):977-88. PubMed ID: 12959187
[TBL] [Abstract][Full Text] [Related]
9. Case of de novo psoriasis possibly triggered by nivolumab.
Murata S; Kaneko S; Harada Y; Aoi N; Morita E
J Dermatol; 2017 Jan; 44(1):99-100. PubMed ID: 27177467
[No Abstract] [Full Text] [Related]
10. PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing L-asparaginase: efficacy and safety.
Chan TSY; Li J; Loong F; Khong PL; Tse E; Kwong YL
Ann Hematol; 2018 Jan; 97(1):193-196. PubMed ID: 28879531
[No Abstract] [Full Text] [Related]
11. The problem with platinum.
Holmes D
Nature; 2015 Nov; 527(7579):S218-9. PubMed ID: 26605762
[No Abstract] [Full Text] [Related]
12. Biomarkers for immune checkpoint inhibitors.
Lievense LA; Hegmans JP; Aerts JG
Lancet Oncol; 2014 Jan; 15(1):e1. PubMed ID: 24384488
[No Abstract] [Full Text] [Related]
13. A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA).
Ngoi NY; Heong V; Ow S; Chay WY; Kim HS; Choi CH; Goss G; Goh JC; Tai BC; Lim DG; Kaliaperumal N; Au VB; Connolly JE; Kim JW; Friedlander M; Kim K; Tan DS
Int J Gynecol Cancer; 2020 Aug; 30(8):1239-1242. PubMed ID: 32591370
[TBL] [Abstract][Full Text] [Related]
14. Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.
Zhu X; Lang J
J Gynecol Oncol; 2017 Sep; 28(5):e64. PubMed ID: 28657225
[TBL] [Abstract][Full Text] [Related]
15. Immunological checkpoint inhibitors enter adolescence.
Nowak AK
Lancet Oncol; 2013 Oct; 14(11):1035-1037. PubMed ID: 24035406
[No Abstract] [Full Text] [Related]
16. Biomarkers for immune checkpoint inhibitors--authors' reply.
Calabrò L; Maio M
Lancet Oncol; 2014 Jan; 15(1):e1-2. PubMed ID: 24384489
[No Abstract] [Full Text] [Related]
17. Immune checkpoint inhibition: therapeutic implications in epithelial ovarian cancer.
Longoria TC; Eskander RN
Recent Pat Anticancer Drug Discov; 2015; 10(2):133-44. PubMed ID: 25938471
[TBL] [Abstract][Full Text] [Related]
18. Management of relapsed/refractory epithelial ovarian cancer: current standards and novel approaches.
Lin H; Changchien CC
Taiwan J Obstet Gynecol; 2007 Dec; 46(4):379-88. PubMed ID: 18182343
[TBL] [Abstract][Full Text] [Related]
19. Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics.
Modesitt SC; Jazaeri AA
Expert Opin Pharmacother; 2007 Oct; 8(14):2293-305. PubMed ID: 17927484
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.
Neal JW; Heist RS; Fidias P; Temel JS; Huberman M; Marcoux JP; Muzikansky A; Lynch TJ; Sequist LV
J Thorac Oncol; 2010 Nov; 5(11):1855-8. PubMed ID: 20975380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
